Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Pharmaust Limited (NUZ) Share Price & Analysis

NUZ Stock Chart & Stats

A$0.09A$0.00(0.00%)
At close: 4:00 PM GMT+11
AU$0.06AU$0.07AU$0.08AU$0.093 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 0.08 - AUD 0.09
52-Week Range
AUD 0.05 - AUD 0.12
Previous Close
AUD 0.09
Volume
246.69K
Average Volume (3M)
277.97K
Market Cap
AUD 68.08M
Enterprise Value
AUD 36.12M
Total Cash (Recent Filing)
AUD 12.71M
Total Debt (Recent Filing)
AUD 3.31M
Price to Earnings (P/E)
―
Beta
0.62
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Capitalization

The sharp increase in equity provides a materially larger capital cushion than the prior year and may improve resilience while the company develops its business. Although losses remain significant, stronger capitalization can support operations and reduce immediate balance-sheet pressure.

Narrower Annual Loss

A reduced net loss indicates some improvement in the earnings trajectory, even though profitability remains far away. If maintained, narrowing losses could slow capital consumption, extend financial runway, and create a more credible path toward eventual operating leverage.

Reduced Cash Burn

The smaller year-on-year cash burn is a constructive change because it suggests pressure on liquidity eased somewhat in 2026. Sustaining this direction would reduce the pace of external funding needs, although absolute cash outflows remain materially negative.

Bears Say

No Recent Revenue

Revenue remaining at zero for three consecutive years indicates that the company has not yet established a recurring commercial base. Without sales generation, operating costs cannot be funded by customers, leaving future progress dependent on financing or successful commercialization.

Persistent Unprofitability

Large continuing losses and frequently negative gross profit point to a business model that has not yet demonstrated sustainable economics. This weak profitability limits internal reinvestment capacity and makes any future growth more costly to finance until margins improve.

Heavy Cash Burn And Funding Dependence

Persistent operating cash outflows, combined with renewed borrowing, indicate ongoing reliance on external funding to maintain activity. This constrains financial flexibility and exposes the company to greater financing pressure while revenue and profitability remain undeveloped.

Pharmaust Limited News

NUZ FAQ

What was Pharmaust Limited’s price range in the past 12 months?
Pharmaust Limited lowest share price was AU$0.05 and its highest was AU$0.12 in the past 12 months.
What is Pharmaust Limited’s market cap?
Pharmaust Limited’s market cap is AU$68.08M.
When is Pharmaust Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmaust Limited’s earnings last quarter?
Pharmaust Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.007 earnings per share for the quarter.
Is Pharmaust Limited overvalued?
According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued.
Does Pharmaust Limited pay dividends?
Pharmaust Limited does not currently pay dividends.
What is Pharmaust Limited’s EPS estimate?
Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaust Limited have?
Pharmaust Limited has 791,652,340 shares outstanding.
What happened to Pharmaust Limited’s price movement after its last earnings report?
Pharmaust Limited reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Pharmaust Limited?
Currently, no hedge funds are holding shares in AU:NUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology